Concert crushed on PhII schizophrenia flop; Amgen's sotorasib gets BTD in China
Concert Pharmaceuticals stock tanked nearly 40% on Monday morning when a major Phase II flop left the biotech no choice but to ax its schizophrenia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
